ABBV Stock Analysis: AbbVie | NYSE
Drug Manufacturers - General | NYSE, USA | Market Cap: 449.454m USD | 12M Return: 39% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 1.80B
EPS Trend: -86.8%
Qual. Beats: 0
Rev. Trend: 88.2%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
AbbVie Inc. is a research-based biopharmaceutical company that conducts the research, development, manufacturing, commercialization, and global sale of medicines and therapies. Its portfolio spans immunology, oncology, neuroscience, eye care, gastroenterology, and medical aesthetics.
Key immunology products include Skyrizi and Rinvoq, while its oncology lineup features Imbruvica, Venclexta, Elahere, Epkinly, and Emrelis. The company also markets Botox (both cosmetic and therapeutic applications), the Juvederm collection of facial fillers, and body contouring and skincare products. Additional franchises cover neurology (Vraylar, Duodopa, Ubrelvy, Qulipta, Vyalev), ophthalmology (Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis), and gastroenterology/hepatology (Mavyret, Creon, Linzess/Constella). The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
As a mega-cap biopharmaceutical company, AbbVie operates a diversified, multi-therapeutic business model that combines patented biologic and small-molecule drugs with consumer-facing aesthetics and eye care brands, relying heavily on continued R&D investment and life-cycle management to offset patent expirations on major products.
- Skyrizi and Rinvoq sales outpace Humira biosimilar erosion
- Botox aesthetic demand softens amid consumer spending pullback
- Dividend hikes and buybacks sustain capital return growth
- Oncology pipeline including Elahere accelerates revenue diversification
| Net Income: 3.64b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.15 > 0.02 and ΔFCF/TA 3.99 > 1.0 |
| NWC/Revenue: -13.64% < 20% (prev -15.21%; Δ 1.57% < -1%) |
| CFO/TA 0.16 > 3% & CFO 21.2b > Net Income 3.64b |
| Net Debt (63.5b) to EBITDA (16.9b): 3.75 < 3 |
| Current Ratio: 0.80 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.77b) vs 12m ago 0.11% < -2% |
| Gross Margin: 70.68% > 18% (prev 70.69%; Δ -0.02% > 0.5%) |
| Asset Turnover: 46.08% > 50% (prev 42.13%; Δ 3.95% > 0%) |
| Interest Coverage Ratio: 3.05 > 6 (EBIT TTM 8.88b / Interest Expense TTM 2.91b) |
| A: -0.06 (Total Current Assets 33.5b - Total Current Liabilities 42.1b) / Total Assets 136b |
| B: -0.13 (Retained Earnings -17.9b / Total Assets 136b) |
| C: 0.07 (EBIT TTM 8.88b / Avg Total Assets 136b) |
| D: -0.05 (Book Value of Equity -6.61b / Total Liabilities 143b) |
| Altman-Z'' = -0.45 = B |
| DSRI: 0.91 (Receivables 12.5b/12.5b, Revenue 62.8b/57.4b) |
| GMI: 1.00 (GM 70.69% / 70.68%) |
| AQI: 0.94 (AQ_t 0.71 / AQ_t-1 0.76) |
| SGI: 1.10 (Revenue 62.8b / 57.4b) |
| TATA: -0.13 (NI 3.64b - CFO 21.2b) / TA 136b) |
| Beneish M = -3.08 (Cap -4..+1) = AA |
As of July 24, 2026, the stock is trading at USD 256.92 with a total of 4,423,377 shares traded. Over the past week, the price has changed by +0.99%, over one month by +10.22%, over three months by +28.76% and over the past year by +39.01%.
Current recommended Stop Loss: 249.50 (which is 2.9% or 1.2 ATR below the current price).
AbbVie has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy ABBV.
- StrongBuy: 12
- Buy: 4
- Hold: 12
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 266.6 | 3.8% |
P/E Trailing = 118.8738
P/E Forward = 17.1821
P/S = 7.1548
P/B = 50.4573
P/EG = 0.399
Revenue TTM = 62.8b USD
EBIT TTM = 8.88b USD
EBITDA TTM = 16.9b USD
Long Term Debt = 64.5b USD (from longTermDebt, last quarter)
Short Term Debt = 8.33b USD (from shortTermDebt, last quarter)
Debt = 72.9b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 63.5b USD (calculated: Debt 72.9b - CCE 9.39b)
Enterprise Value = 513b USD (449b + Debt 72.9b - CCE 9.39b)
Interest Coverage Ratio = 3.05 (Ebit TTM 8.88b / Interest Expense TTM 2.91b)
EV/FCF = 24.58x (Enterprise Value 513b / FCF TTM 20.9b)
FCF Yield = 4.07% (FCF TTM 20.9b / Enterprise Value 513b)
FCF Margin = 33.21% (FCF TTM 20.9b / Revenue TTM 62.8b)
Net Margin = 5.79% (Net Income TTM 3.64b / Revenue TTM 62.8b)
Gross Margin = 70.68% ((Revenue TTM 62.8b - Cost of Revenue TTM 18.4b) / Revenue TTM)
Gross Margin QoQ = 71.88% (prev 72.61%)
Tobins Q-Ratio = 3.76 (Enterprise Value 513b / Total Assets 136b)
Interest Expense / Debt = 3.99% (Interest Expense 2.91b / Debt 72.9b)
Taxrate = 39.06% (2.33b / 5.97b)
NOPAT = 5.41b (EBIT 8.88b * (1 - 39.06%))
Current Ratio = 0.80 (Total Current Assets 33.5b / Total Current Liabilities 42.1b)
Debt / Equity = -11.02 (negative equity) (Debt 72.9b / totalStockholderEquity, last quarter -6.61b)
Debt / EBITDA = 3.75 (Net Debt 63.5b / EBITDA 16.9b)
Debt / FCF = 3.04 (Net Debt 63.5b / FCF TTM 20.9b)
Total Stockholder Equity = -3.14b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.67% (Net Income 3.64b / Total Assets 136b)
RoE = -115.7% (negative equity) (Net Income TTM 3.64b / Total Stockholder Equity -3.14b)
RoCE = 14.47% (EBIT 8.88b / Capital Employed (Equity -3.14b + L.T.Debt 64.5b))
RoIC = 5.44% (NOPAT 5.41b / Invested Capital 99.5b)
WACC = 6.10% (E(449b)/V(522b) * Re(6.70%) + D(72.9b)/V(522b) * Rd(3.99%) * (1-Tc(0.39)))
Discount Rate = 6.70% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 54.76 | Cagr: 0.05%
[DCF] Terminal Value 77.97% ; FCFF base≈18.7b ; Y1≈21.4b ; Y5≈31.5b
[DCF] Fair Price = 232.4 (EV 474b - Net Debt 63.5b = Equity 411b / Shares 1.77b; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -86.78 | EPS CAGR: -7.31% | SUE: -0.66 | # QB: 0
Revenue Correlation: 88.25 | Revenue CAGR: 4.78% | SUE: 0.63 | # QB: 0
EPS current Quarter (2026-06-30): EPS=3.67 | Chg30d=-2.53% | Revisions=+0% | Analysts=20
EPS next Quarter (2026-09-30): EPS=3.84 | Chg30d=-0.27% | Revisions=-17% | Analysts=17
EPS current Year (2026-12-31): EPS=14.15 | Chg30d=-0.72% | Revisions=+0% | GrowthEPS=+41.5% | GrowthRev=+10.0%
EPS next Year (2027-12-31): EPS=16.28 | Chg30d=+0.15% | Revisions=-38% | GrowthEPS=+15.1% | GrowthRev=+8.3%
[Analyst] Revisions Ratio: -24% (up=5, down=9)